BofA initiates recently public Omthera Pharmaceuticals (OMTH +7.5%) at Buy with a $10 price target, saying the company "has a compelling valuation compared to the only other omega-3 pure play [and] Epanova has significant growth potential [but] does not have to become a blockbuster" for the stock to rise. Similarly, Leerink Swann starts the stock at Outperform ($12 price target) citing a positive outlook for Epanova, and Piper Jaffray assumes coverage at Overweight with a target of $15.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs